Drug

Articaine

As of the edition of 20 October 2026, Articaine is a small molecule: marketed, first approved in 1979 (ES); acts on SCN10A, SCN11A and SCN1A and 7 more; no US protection of its own is listed.

Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.

The drug

Status: Marketed; latest approval 2024
Kind: Small molecule
Brand name: Septocaine
First approved: 1 June 1979 (ES)
Approvals on record: 10 in 5 regions
Holder of the most recent approval: Thea Pharma; 7 holders in all
Registered trials: 52, 4 stopped early
Disease areas: Mouth and teeth; Inherited and neonatal; Nervous system; Heart and blood vessels; Pregnancy and women's health; Urinary and reproductive

US protection

No US protection of its own is listed.

The FDA registers list no drug-substance patent or exclusivity of its own that counts for this drug.

Thea Pharma holds a later exclusivity on its own new formulation or combination product, ending 2028; it does not protect the original drug.

This is the US only.

Targets

Gene	Protein	UniProt
SCN1A	Sodium channel protein type 1 subunit alpha	P35498
SCN4A	Sodium channel protein type 4 subunit alpha	P35499
SCN7A	Sodium channel protein type 7 subunit alpha	Q01118
SCN5A	Sodium channel protein type 5 subunit alpha	Q14524
SCN9A	Sodium channel protein type 9 subunit alpha	Q15858
SCN2A	Sodium channel protein type 2 subunit alpha	Q99250
SCN3A	Sodium channel protein type 3 subunit alpha	Q9NY46
SCN11A	Sodium channel protein type 11 subunit alpha	Q9UI33
SCN8A	Sodium channel protein type 8 subunit alpha	Q9UQD0
SCN10A	Sodium channel protein type 10 subunit alpha	Q9Y5Y9

Gene

Protein

UniProt

SCN1A

Sodium channel protein type 1 subunit alpha

P35498

SCN4A

Sodium channel protein type 4 subunit alpha

P35499

SCN7A

Sodium channel protein type 7 subunit alpha

Q01118